(Q34858284)

4 August 2017

Adjuvant chemotherapy in older women with early-stage breast cancer (English)

1 reference

4 August 2017

1 reference

1 reference

Antonio C Wolff

14

0 references

Larry Norton

Larry Norton

22

0 references

Barbara A Parker

19

Barbara A Parker

1 reference

4 August 2017

1

Hyman B Muss

1 reference

4 August 2017

7

Ann H Partridge

1 reference

4 August 2017

13

Edith A Perez

1 reference

4 August 2017

Constance T Cirrincione

3

Constance T Cirrincione

1 reference

4 August 2017

23

Clifford A Hudis

1 reference

4 August 2017

24

Eric P Winer

1 reference

4 August 2017

15

Julie R Gralow

1 reference

4 August 2017

2

Donald A Berry

1 reference

4 August 2017

10

Heather P Becker

1 reference

4 August 2017

5

Ann M Mauer

1 reference

4 August 2017

6

Alice B Kornblith

1 reference

4 August 2017

8

Lynn G Dressler

1 reference

4 August 2017

9

Harvey J Cohen

1 reference

4 August 2017

Patricia A Kartcheske

11

Patricia A Kartcheske

1 reference

4 August 2017

20

Ronald D Hart

1 reference

4 August 2017

21

Debjani Grenier

1 reference

4 August 2017

4

Maria Theodoulou

1 reference

4 August 2017

Judith D Wheeler

12

1 reference

4 August 2017

Harold J Burstein

16

1 reference

4 August 2017

Ahmad A Mahmood

17

1 reference

4 August 2017

Gustav Magrinat

18

1 reference

4 August 2017

CALGB Investigators

25

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

The New England Journal of Medicine

4 August 2017

1 reference

4 August 2017

360

1 reference

4 August 2017

20

1 reference

4 August 2017

2055-2065

1 reference

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

8 July 2018

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Effect of screening and adjuvant therapy on mortality from breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Clinical status of capecitabine in the treatment of breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Patient preferences for oral versus intravenous palliative chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Barriers to clinical trial participation by older women with breast cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Participation of patients 65 years of age or older in cancer clinical trials.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3082436

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

9 December 2018

1 reference

12 December 2020

How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

12 December 2020

Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women

1 reference

12 December 2020

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

12 December 2020

Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk

1 reference

12 December 2020

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0810266

1 reference

4 August 2017

1 reference

4 August 2017

1 reference